Generics
What is the meaning of a narrow therapeutic index?
What is the meaning of a narrow therapeutic index (NTI) is a topic explained by author Roy G Beran, in a mini review [1].
Canada calls for support to national pharmacare and generics industry
Canada has made a federal budget commitment to supporting a national pharmacare programme. This can be bolstered through strengthening Canada’s domestic generics pharmaceutical industry.
What is meant by a generic medication and generic equivalence?
Author Professor Roy G Beran, in a mini review, explains what generics are and what is meant by generic equivalence [1].
Consequences of generics being favoured by healthcare providers
Generics are favoured by healthcare providers due to a variety pf reasons, according to author Roy G Beran [1].
UK NHS faces drug shortages
The United Kingdom’s (UK) National Health Service (NHS) faces shortages of blood pressure pills, painkillers and antidepressants due to drug manufacturer supply problems.
The cost of developing drugs and use of generics
In a mini review, author Professor Roy G Beran explains how generics can be produced at a much lower cost than originator drugs [1].
Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
Regulatory bioequivalence rules for generics are well established and recognized. However, proving bioequivalence may not always be so easy, especially with drugs with a narrow therapeutic index (NTI) [1].
Repurposing generic drugs can save time and money
Repurposing generic drugs for new indications could save time and money compared to developing new treatments and represent a cost-effective way of addressing unmet medical needs, argues a new article by a University of Michigan professor [1].
Availability of medicines and the sustainable development of the national health system in Russia
The modernization of the drug supply system for citizens as a multifaceted process that ensures the sustainable development of the national health system is the focus of attention of the economy, the state and society. In order to study this, authors from Russia carried out a study to analyse the availability of medicines for the population for the treatment of cardiovascular diseases in 2011 and 2019 [1].
Five Chinese companies join UN’s MPP for Covid-19 medicines
Five pharmaceutical companies in China have signed up to the United Nation’s (UN) Medicine Patent Pool (MPP) which will allow them to produce generic versions of Pfizer's oral COVID-19 treatment, Paxlovid (nirmatrelvir/ritonavir), for distribution in 95 low- and middle-income countries, approximately 53 per cent of the world's population.
